Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 3
2015 2
2016 1
2017 1
2018 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells.
Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, Hair J, Jones DC, Hasani S, Wang B, Im SA, Tran B, Subramaniam DS, Gainer SD, Vashisht K, Lewis A, Jin X, Kentner S, Mulgrew K, Wang Y, Overstreet MG, Dodgson J, Wu Y, Palazon A, Morrow M, Rainey GJ, Browne GJ, Neal F, Murray TV, Toloczko AD, Dall'Acqua W, Achour I, Freeman DJ, Wilkinson RW, Mazor Y. Dovedi SJ, et al. Cancer Discov. 2021 May;11(5):1100-1117. doi: 10.1158/2159-8290.CD-20-1445. Epub 2021 Jan 8. Cancer Discov. 2021. PMID: 33419761
Phase II study of MEDI-575, an anti-platelet-derived growth factor-alpha antibody, in patients with recurrent glioblastoma.
Phuphanich S, Raizer J, Chamberlain M, Canelos P, Narwal R, Hong S, Miday R, Nade M, Laubscher K. Phuphanich S, et al. J Neurooncol. 2017 Jan;131(1):185-191. doi: 10.1007/s11060-016-2287-6. Epub 2016 Nov 14. J Neurooncol. 2017. PMID: 27844311 Clinical Trial.
MEDI-575, an immunoglobulin G2kappa monoclonal antibody, selectively binds to platelet-derived growth factor-alpha receptor (PDGFR-alpha) with high specificity. ...MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblasto …
MEDI-575, an immunoglobulin G2kappa monoclonal antibody, selectively binds to platelet-derived growth factor-alpha receptor (P …
A Phase I study of MEDI-575, a PDGFRalpha monoclonal antibody, in Japanese patients with advanced solid tumors.
Murakami H, Ikeda M, Okusaka T, Inaba Y, Iguchi H, Yagawa K, Yamamoto N. Murakami H, et al. Cancer Chemother Pharmacol. 2015 Sep;76(3):631-9. doi: 10.1007/s00280-015-2832-6. Epub 2015 Jul 30. Cancer Chemother Pharmacol. 2015. PMID: 26223436 Clinical Trial.
PURPOSE: MEDI-575 is a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor alpha (PDGFRalpha). ...MEDI-575 binding with PDGFRalpha resulted in a dose-dependent increase in PDGF-AA ligand, with plateau level …
PURPOSE: MEDI-575 is a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor alpha …
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
Wheatley-Price P, Gadgeel S, Takahashi T, Li X, Dar M, Blumenschein GR Jr. Wheatley-Price P, et al. Clin Lung Cancer. 2019 May;20(3):e362-e368. doi: 10.1016/j.cllc.2018.11.012. Epub 2018 Nov 29. Clin Lung Cancer. 2019. PMID: 30685114 Clinical Trial.
This randomized phase 1b/2 trial investigated the addition of the anti-PDGFRalpha monoclonal antibody MEDI-575 to first-line carboplatin/paclitaxel (CP) chemotherapy. PATIENTS AND METHODS: The phase 1b component was a dose-escalation study combining MEDI-5 …
This randomized phase 1b/2 trial investigated the addition of the anti-PDGFRalpha monoclonal antibody MEDI-575 to first-line c …
A phase I dose-escalation study of MEDI-575, a PDGFRalpha monoclonal antibody, in adults with advanced solid tumors.
Becerra CR, Conkling P, Vogelzang N, Wu H, Hong S, Narwal R, Liang M, Tavakkoli F, Pandya N. Becerra CR, et al. Cancer Chemother Pharmacol. 2014 Nov;74(5):917-25. doi: 10.1007/s00280-014-2567-9. Epub 2014 Aug 23. Cancer Chemother Pharmacol. 2014. PMID: 25149088 Free PMC article. Clinical Trial.
METHODS: This phase I multicenter, open-label, single-arm study enrolled adults in a 3 + 3 dose escalation design to receive MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly (QW) until toxicity or disease progression occurred. ...With no reports of dose-limiting toxi …
METHODS: This phase I multicenter, open-label, single-arm study enrolled adults in a 3 + 3 dose escalation design to receive MEDI- …
Inhibition of platelet-derived growth factor receptor alpha by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N, McDermott B, Wen S, Yang D, Lawson D, Collins M, Reimer C, Hall PA, Andersén H, Snaith M, Wang X, Bedian V, Cao ZA, Blakey D. Laing N, et al. Mol Pharmacol. 2013 Jun;83(6):1247-56. doi: 10.1124/mol.112.084079. Epub 2013 Apr 4. Mol Pharmacol. 2013. PMID: 23558446
Additional in vitro studies indicated that exposure of primary cancer-associated fibroblasts to MEDI-575 can directly affect proliferation and key signaling pathways in these cells. These results highlight the potential for observing antitumor activity with MEDI …
Additional in vitro studies indicated that exposure of primary cancer-associated fibroblasts to MEDI-575 can directly affect p …
A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. Liang M, et al. AAPS J. 2020 Nov 18;23(1):4. doi: 10.1208/s12248-020-00523-3. AAPS J. 2020. PMID: 33210183
Tovetumab (MEDI-575) is a fully human IgG2kappa monoclonal antibody that specifically binds to human platelet-derived growth factor receptor alpha (PDGFRalpha) and blocks receptor signal transduction by PDGF ligands. ...As such, PDGF-AA accumulation is an ind …
Tovetumab (MEDI-575) is a fully human IgG2kappa monoclonal antibody that specifically binds to human platelet-derived g …
Discontinued in 2013: oncology drugs.
Williams R. Williams R. Expert Opin Investig Drugs. 2015 Jan;24(1):95-110. doi: 10.1517/13543784.2015.971154. Epub 2014 Oct 14. Expert Opin Investig Drugs. 2015. PMID: 25315907
Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay.
Schwickart M, Mehrzai F, Pearson J, Shaghasi N, Chavez C, Schneider A, Wu S, Roskos L, Liang M. Schwickart M, et al. J Immunol Methods. 2014 Jan 31;403(1-2):52-61. doi: 10.1016/j.jim.2013.11.018. Epub 2013 Nov 25. J Immunol Methods. 2014. PMID: 24287421 Free article.
We developed a method to detect neutralizing antibodies against MEDI-575, a fully human IgG2kappa antagonistic antibody against PDGFR-alpha. ...
We developed a method to detect neutralizing antibodies against MEDI-575, a fully human IgG2kappa antagonistic antibody agains …
Circulating tumor cells: application as a biomarker for molecular characterization and predictor of survival in an all-comer solid tumor phase I clinical study.
Bao H, Burke PA, Huang J, Chen X, Brohawn PZ, Yao Y, Lechleider RJ, Sikorski RS, Buzoianu M, Zhang J, Shi X, Richman LK, Lavallee TM. Bao H, et al. PLoS One. 2013 Aug 21;8(8):e58557. doi: 10.1371/journal.pone.0058557. eCollection 2013. PLoS One. 2013. PMID: 23990866 Free PMC article. Clinical Trial.
EXPERIMENTAL DESIGN: Blood samples for CTC analysis were obtained from 24 cancer patients in a multi-center all-comer Phase I study of MEDI-575, a novel anti-PDGFRalpha antibody. Samples were taken at screening and analyzed for enumeration of CTC using the CellSearc …
EXPERIMENTAL DESIGN: Blood samples for CTC analysis were obtained from 24 cancer patients in a multi-center all-comer Phase I study of ME …